BeOne Medicines (ONC) Revenue (2015 - 2026)
BeOne Medicines (ONC) posted quarterly Revenue of $1.5 billion for Q1 2026, up 35.46% year-over-year from $1.1 billion in Q1 2025, and up 1.02% quarter-over-quarter from $1.5 billion in Q4 2025.
BeOne Medicines (ONC) Revenue (2015 - 2026) Analysis & Trends
BeOne Medicines (ONC) has reported Revenue for 12 consecutive years, with $1.5 billion the latest figure, recorded in Q1 2026.
- In Q1 2026, Revenue rose 35.46% year-over-year to $1.5 billion; the TTM figure through Mar 2026 stood at $5.7 billion (up 37.44% YoY), while the FY2025 annual figure was $5.3 billion, up 40.23% from the prior year.
- Revenue advanced to $1.5 billion in Q1 2026 per ONC's latest filing, from $1.5 billion in the prior quarter.
- Across five years, Revenue topped out at $1.5 billion in Q1 2026 and bottomed at $306.6 million in Q1 2022.
- Historically, Revenue has averaged $855.4 million across 5 years, with a median of $781.3 million in 2023.
- On a YoY basis, Revenue climbed as much as 127.73% in 2022 and fell as far as 49.39% in 2022.
- BeOne Medicines' Revenue stood at $380.1 million in 2022, then surged by 66.91% to $634.4 million in 2023, then surged by 77.78% to $1.1 billion in 2024, then jumped by 32.84% to $1.5 billion in 2025, then grew by 1.02% to $1.5 billion in 2026.
- Business Quant data shows ONC's Revenue at $1.5 billion in Q1 2026, $1.5 billion in Q4 2025, and $1.4 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.33 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 4.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.56 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.71 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3,001.92 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 674.14 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.29 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 425.49 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | 1.44 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.71 Bn |
| Mar 31, 2026 | 1.51 Bn |
| Dec 31, 2025 | 1.50 Bn |
| Sep 30, 2025 | 1.41 Bn |
| Jun 30, 2025 | 1.32 Bn |
| Mar 31, 2025 | 1.12 Bn |
| Dec 31, 2024 | 1.13 Bn |
| Sep 30, 2024 | 1.00 Bn |
| Jun 30, 2024 | 929.17 Mn |
| Mar 31, 2024 | 751.65 Mn |
| Dec 31, 2023 | 634.41 Mn |
| Sep 30, 2023 | 781.31 Mn |
| Jun 30, 2023 | 595.26 Mn |
| Mar 31, 2023 | 447.80 Mn |
| Dec 31, 2022 | 380.10 Mn |
| Sep 30, 2022 | 387.63 Mn |
| Jun 30, 2022 | 341.57 Mn |
| Mar 31, 2022 | 306.63 Mn |
| Dec 31, 2021 | 213.98 Mn |
| Sep 30, 2021 | 206.44 Mn |